Shanghai Fosun Pharmaceutical Industrial Development
Pre-Approval PRO BETAPipeline by Phase
Therapeutic Focus
Clinical Trials (16)
FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration
Started: 6/30/2025
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Started: 6/20/2023
Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC
Started: 12/31/2021
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU
Started: 1/29/2026
To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH
Started: 9/28/2023
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
Started: 6/1/2026
FXS6837 for the Treatment of IgAN Patients
Started: 3/31/2026
FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms
Started: 8/16/2023
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
Started: 5/15/2026
Phase I Study of FXS887 in the Treatment of Solid Tumors
Started: 1/5/2026
Phase 1 Study of FS-1502 in Patients With HER2 Expressed Advanced Solid Tumors and Breast Cancer.
Started: 10/11/2019
Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1
Started: 6/12/2025
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
Started: 3/26/2021
MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)
Started: 3/21/2019
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
Started: 7/23/2018
Phase I Study of FXS0683 in the Treatment of Blood Tumors
Started: 6/1/2026